Skip to main content
Biosimilars
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for the Treatment of High-Risk, HER2-Positive Early Breast Cancer
Read More
Biosimilars
Real-World Overall Response Rate and Other Outcomes Related to Originator and Biosimilar Rituximab in Patients with CLL or NHL in the United Kingdom
Read More
Lung Cancer
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
Read More
Lung Cancer
KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC
Read More
Lung Cancer
CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups
Read More
Lung Cancer
NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC
Read More
Lung Cancer
The Effect of Various KRAS Mutations on NSCLC Susceptibility
Read More
Lung Cancer
Patterns of Biomarker Testing in Metastatic NSCLC in the Community Oncology Setting
Read More
Lung Cancer
Adagrasib Shows Promising Results in Pretreated KRAS Mutation–Positive NSCLC
Read More
Lung Cancer
Precision Medicine in Cancer Therapy: Improving Access
Read More
Page 71 of 196
Results 701 - 710 of 1953